Cardiometabolic Risk Factors in Rosuvastatin-Treated Men with Mixed Dyslipidemia and Early-Onset Androgenic Alopecia

A study investigated the effects of rosuvastatin treatment on cardiometabolic risk factors in men with mixed dyslipidemia and early-onset androgenic alopecia. The study found that rosuvastatin treatment improved lipid profiles and reduced inflammation markers in men with mixed dyslipidemia and early-onset androgenic alopecia, but did not have a significant effect on androgenic alopecia. However, it negatively affected insulin sensitivity in the hair loss group. Men with early-onset androgenic alopecia have increased levels of cardiometabolic risk factors, and early screening and management of these risk factors is important for this population. Rosuvastatin treatment can be beneficial for men with mixed dyslipidemia and early-onset androgenic alopecia by improving lipid profiles and reducing cardiometabolic risk factors, potentially lowering their risk for cardiovascular disease.